Patisiran
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Patisiran
- Patisiran: From Hereditary Transthyretin Amyloidosis to Dermatitis (Low-Confidence Prediction)
Patisiran: From Hereditary Transthyretin Amyloidosis to Dermatitis (Low-Confidence Prediction)
One-Sentence Summary
Patisiran is an siRNA-lipid nanoparticle (LNP) therapeutic originally developed to silence TTR mRNA for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis. The TxGNN model’s top-ranked prediction is Dermatitis, but this candidate is supported by 0 clinical trials and 0 publications, and the evidence pack’s own mechanistic assessment finds no known biological link between TTR gene silencing and inflammatory skin disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hereditary transthyretin (ATTR) amyloidosis (based on drug class context; no formal EU/TW label text available — drug not marketed) |
| Predicted New Indication | Dermatitis |
| TxGNN Prediction Score | 90.65% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a blocking data gap). Based on known drug-class information, Patisiran is an siRNA-LNP therapeutic that silences hepatic TTR mRNA production, reducing circulating transthyretin protein and thereby slowing amyloid fibril deposition in peripheral nerves and the heart. Its established clinical role is in hereditary transthyretin amyloidosis with polyneuropathy — an entirely distinct disease category from dermatitis.
The evidence pack’s own mechanistic rationale for this prediction is explicit that no known biological connection exists between RNA interference-mediated TTR suppression and dermatitis’s inflammatory pathways. The TxGNN score of 90.65% most likely reflects an indirect node connection within the knowledge graph (e.g., shared downstream pathways or co-occurring metadata) rather than genuine pharmacological plausibility. Because the model output is unaccompanied by any clinical trial or literature evidence, this candidate should be treated as a hypothesis-generating signal only, not as a validated repurposing lead.
It is worth noting that a lower-ranked candidate in this pack — overactive bladder (rank 9, score 84.9%) — has a more coherent (though still indirect) rationale: hATTR amyloidosis itself can cause autonomic neuropathy leading to bladder dysfunction, so improvement in bladder symptoms could theoretically follow from treating the underlying amyloidosis. This represents disease comorbidity rather than a direct new indication, but may warrant closer review before dermatitis in any follow-up evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Patisiran currently has no marketing authorizations recorded in this dataset (0 licenses, market status: Not marketed). No product/indication label text is available for cross-reference.
Safety Considerations
Please refer to the SmPC for safety information. (Key warnings, contraindications, and drug-interaction data are currently unavailable — TFDA label retrieval is flagged as a blocking data gap.)
Conclusion and Next Steps
Decision: Hold
Rationale: This is a pure L5 model-only prediction (TxGNN score without corroborating clinical or literature evidence), and the evidence pack’s own mechanistic review finds no biological rationale linking TTR-targeted siRNA therapy to dermatitis. Advancing this candidate is not justified at this stage.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data from DrugBank (DG002)
- TFDA/EMA label warnings and contraindications to enable a baseline safety screen (DG001, blocking)
- Independent preclinical or mechanistic evidence connecting TTR silencing to dermatitis pathophysiology, if this candidate is to be pursued further
- Consideration of re-scoping toward higher-plausibility candidates in this pack (e.g., overactive bladder, rank 9) given the disease-comorbidity link to hATTR amyloidosis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.